Collateral damage of NUDT15 deficiency in cancer provides a cancer pharmacogenetic therapeutic window with thiopurines
J. C. Massey, J. Magagnoli, S. S. Sutton, P. Buckhaults, M. D. Wyatt
The paper identifies that NUDT15 loss in cancer cells creates a therapeutic window for thiopurines, showing increased sensitivity in cancer cell lines and reduced prostate cancer incidence with thiopurine and xanthine oxidase inhibitor co-treatment.
bioRxiv · Apr 8, 2024 · PreprintPharmacology & Toxicology